103 related articles for article (PubMed ID: 38755703)
1. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
3. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
4. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract][Full Text] [Related]
5. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.
Saloner R; VandeVrede L; Asken BM; Paolillo EW; Gontrum EQ; Wolf A; Lario-Lago A; Milà-Alomà M; Triana-Baltzer G; Kolb HC; Dubal DB; Rabinovici GD; Miller BL; Boxer AL; Casaletto KB; Kramer JH
Alzheimers Dement; 2024 Jan; 20(1):376-387. PubMed ID: 37639492
[TBL] [Abstract][Full Text] [Related]
6. Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population.
Ohara T; Tatebe H; Hata J; Honda T; Shibata M; Matsuura S; Mikami T; Maeda T; Ono K; Mimura M; Nakashima K; Iga JI; Takebayashi M; Tokuda T; Ninomiya T;
Psychiatry Clin Neurosci; 2024 Jun; 78(6):362-371. PubMed ID: 38606661
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
8. Predicting future rates of tau accumulation on PET.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Whitwell J; Josephs K; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
Brain; 2020 Oct; 143(10):3136-3150. PubMed ID: 33094327
[TBL] [Abstract][Full Text] [Related]
9. Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer's Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study.
Shim Y
Curr Alzheimer Res; 2023; 20(10):715-724. PubMed ID: 38299421
[TBL] [Abstract][Full Text] [Related]
10. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change.
Smirnov DS; Ashton NJ; Blennow K; Zetterberg H; Simrén J; Lantero-Rodriguez J; Karikari TK; Hiniker A; Rissman RA; Salmon DP; Galasko D
Acta Neuropathol; 2022 Apr; 143(4):487-503. PubMed ID: 35195758
[TBL] [Abstract][Full Text] [Related]
11. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.
Smith R; Cullen NC; Pichet Binette A; Leuzy A; Blennow K; Zetterberg H; Klein G; Borroni E; Ossenkoppele R; Janelidze S; Palmqvist S; Mattsson-Carlgren N; Stomrud E; Hansson O;
Alzheimers Dement; 2023 Jun; 19(6):2497-2507. PubMed ID: 36516028
[TBL] [Abstract][Full Text] [Related]
12. Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.
Guzmán-Vélez E; Zetterberg H; Fox-Fuller JT; Vila-Castelar C; Sanchez JS; Baena A; Garcia-Ospina G; Aguillon D; Pardilla-Delgado E; Gatchel JR; Sperling RA; Johnson K; Reiman EM; Blennow K; Lopera F; Quiroz YT
Alzheimers Dement; 2021 May; 17(5):813-821. PubMed ID: 33527648
[TBL] [Abstract][Full Text] [Related]
13. Predicting amyloid PET and tau PET stages with plasma biomarkers.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Figdore DJ; Schwarz CG; Lowe VJ; Ramanan VK; Vemuri P; Mielke MM; Knopman DS; Graff-Radford J; Boeve BF; Kantarci K; Cogswell PM; Senjem ML; Gunter JL; Therneau TM; Petersen RC
Brain; 2023 May; 146(5):2029-2044. PubMed ID: 36789483
[TBL] [Abstract][Full Text] [Related]
14. Performance of a [
Coomans EM; de Koning LA; Rikken RM; Verfaillie SCJ; Visser D; den Braber A; Tomassen J; van de Beek M; Collij LE; Lemstra AW; Windhorst AD; Barkhof F; Golla SSV; Visser PJ; Scheltens P; van der Flier WM; Ossenkoppele R; van Berckel BNM; van de Giessen E
Neurology; 2023 Nov; 101(19):e1850-e1862. PubMed ID: 37748892
[TBL] [Abstract][Full Text] [Related]
15. [Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease].
Blennow K; Hansson O
Lakartidningen; 2024 May; 121():. PubMed ID: 38818759
[TBL] [Abstract][Full Text] [Related]
16. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
Yang HS; Yau WW; Carlyle BC; Trombetta BA; Zhang C; Shirzadi Z; Schultz AP; Pruzin JJ; Fitzpatrick CD; Kirn DR; Rabin JS; Buckley RF; Hohman TJ; Rentz DM; Tanzi RE; Johnson KA; Sperling RA; Arnold SE; Chhatwal JP
Brain; 2024 Jun; 147(6):2158-2168. PubMed ID: 38315899
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ATN
Cousins KAQ; Irwin DJ; Tropea TF; Rhodes E; Phillips J; Chen-Plotkin AS; Brumm MC; Coffey CS; Kang JH; Simuni T; Foroud TM; Toga AW; Tanner CM; Kieburtz KD; Mollenhauer B; Galasko D; Hutten S; Weintraub D; Siderowf AD; Marek K; Poston KL; Shaw LM;
Neurology; 2024 Feb; 102(4):e208033. PubMed ID: 38306599
[TBL] [Abstract][Full Text] [Related]
18. Central autonomic network dysfunction and plasma Alzheimer's disease biomarkers in older adults.
Lohman T; Kapoor A; Engstrom AC; Shenasa F; Alitin JPM; Gaubert A; Rodgers KE; Bradford D; Mather M; Han SD; Head E; Sordo L; Thayer JF; Nation DA
Alzheimers Res Ther; 2024 Jun; 16(1):124. PubMed ID: 38851772
[TBL] [Abstract][Full Text] [Related]
19. Serum Markers of Neurodegeneration Are Strongly Linked to Heart Failure Severity and Outcome.
Wurm R; Prausmüller S; Ponleitner M; Spinka G; Weidenhammer A; Arfsten H; Heitzinger G; Panagiotides NG; Strunk G; Bartko P; Goliasch G; Stögmann E; Hengstenberg C; Hülsmann M; Pavo N
JACC Heart Fail; 2024 Jun; 12(6):1073-1085. PubMed ID: 38839151
[TBL] [Abstract][Full Text] [Related]
20. Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men.
Tang R; Buchholz E; Dale AM; Rissman RA; Fennema-Notestine C; Gillespie NA; Hagler DJ; Lyons MJ; Neale MC; Panizzon MS; Puckett OK; Reynolds CA; Franz CE; Kremen WS; Elman JA
Alzheimers Res Ther; 2024 Apr; 16(1):90. PubMed ID: 38664843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
